Overview

ATG-F VS ATG for the Prevention of GVHD

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

Anti-thymocyte globulin (ATG) preparative regimen in the setting of haploidentical stem cell transplantation (haplo-HSCT) is vital for inducing immune tolerance.The study aims to compare the efficacy and safety of ATG-F vs ATG, incorporated into the preparative regimens for haplo-identical transplants.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Fujian Medical University

Treatments:

Immunosuppressive Agents